Dement Neurocogn Disord.  2012 Dec;11(4):136-140. 10.12779/dnd.2012.11.4.136.

Is There the Preventive Effect of COMT-inhibitor on Parkinson's Disease Associated with Dementia?

Affiliations
  • 1Department of Neurology, College of Medicine, The Catholic University of Korea, Seoul, Korea. siuy@cmcnu.or.kr
  • 2Department of Neurology, Veterans Hospital, Seoul Medical Center, Seoul, Korea.

Abstract

BACKGROUND
Elevated homocysteine (hcy) levels are associated with dementia, which is a frequent non-motor symptom of Parkinson's disease (PD). High levels of hcy in PD patients treated with levodopa are thought to result from increased synthesis during the metabolism of levodopa by COMT, and that use of a COMT-inhibitor may reduce hcy levels. In this study, we sought to clarify the effects of COMT-inhibitors on dementia in PD patients.
METHODS
Thirty-eight PD patients without dementia (PDwoD), 35 PD patients with dementia (PDD), and 48 controls were enrolled in this study. All subjects underwent neuropsychological testing and a neurological examination. The hcy levels were measured in all subjects, and the relationship between hcy levels and dementia was evaluated in two PD groups (those that underwent treatment with levodopa-alone versus treatment with levodopa plus a COMT-inhibitor).
RESULTS
Patients in the PDD group showed higher hcy levels than patients in the PDwoD group, though there was no significant difference in the hcy level between PDwoD patients and healthy controls. Regarding the effects of a COMT-inhibitor, there was no correlation between hcy levels in the 2 PD subgroups, indicating that there were no significant effects of the COMT-inhibitor on PDD. In addition, the odds ratio for PDD with the use of a COMT-inhibitor was 0.864 (95% CI=0.342-2.180).
CONCLUSIONS
These results are in agreement with previous studies in that levodopa treatment in PD patients leads to elevated hcy concentrations. COMT-inhibitors, on the other hand, had no preventive effect on cognitive impairment in PD patients.

Keyword

Parkinson's disease; Dementia; COMT-inhibitor; Homocysteine

MeSH Terms

Dementia
Hand
Homocysteine
Humans
Levodopa
Neurologic Examination
Neuropsychological Tests
Odds Ratio
Parkinson Disease
Homocysteine
Levodopa

Reference

1. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, et al. Plasma homocysteine as a risk factor for dementia and alzheimer's disease. N Engl J Med. 2002. 346:476–483.
Article
2. Zoccolella S, Lamberti SV, Iliceto G, Santamato A, Lamberti P, Logroscino G. Hyperhomocysteinemia in l-dopa treated patients with parkinson's disease: potential implications in cognitive dysfunction and dementia? Curr Med Chem. 2010. 17:3253–3261.
Article
3. Ramakrishnan S, Sulochana KN, Lakshmi S, Selvi R, Angayarkanni N. Biochemistry of homocysteine in health and diseases. Indian J Biochem Biophys. 2006. 43:275–283.
Article
4. Rodriguez-Oroz MC, Lage PM, Sanchez-Mut J, Lamet I, Pagonabarraga J, Toledo JB, et al. Homocysteine and cognitive impairment in parkinson's disease: a biochemical, neuroimaging, and genetic study. Mov Disord. 2009. 24:1437–1444.
Article
5. O'Suilleabhain PE, Bottiglieri T, Dewey RB Jr, Sharma S, Diaz-Arrastia R. Modest increase in plasma homocysteine follows levodopa initiation in parkinson's disease. Mov Disord. 2004. 19:1403–1408.
Article
6. Wald DS, Kasturiratne A, Simmonds M. Serum homocysteine and dementia: meta-analysis of eight cohort studies including 8669 participants. Alzheimers Dement. 2011. 7:412–417.
Article
7. Muller T. Role of homocysteine in the treatment of parkinson's disease. Expert Rev Neurother. 2008. 8:957–967.
Article
8. Lamberti P, Zoccolella S, Iliceto G, Armenise E, Fraddosio A, de Mari M, et al. Effects of levodopa and comt inhibitors on plasma homocysteine in parkinson's disease patients. Mov Disord. 2005. 20:69–72.
Article
9. Nissinen E, Nissinen H, Larjonmaa H, Vaananen A, Helkamaa T, Reenila I, et al. The comt inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats. J Neural Transm. 2005. 112:1213–1221.
Article
10. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992. 55:181–184.
Article
11. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with lewy bodies: third report of the dlb consortium. Neurology. 2005. 65:1863–1872.
Article
12. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967. 17:427–442.
Article
13. Zoccolella S, dell'Aquila C, Abruzzese G, Antonini A, Bonuccelli U, Canesi M, et al. Hyperhomocysteinemia in levodopa-treated patients with parkinson's disease dementia. Mov Disord. 2009. 24:1028–1033.
Article
14. Nevrly M, Kanovsky P, Vranova H, Langova K, Hlustik P. Effect of levodopa and entacapone treatment on plasma homocysteine levels in parkinsons disease patients. Parkinsonism Relat Disord. 2009. 15:477–478.
Article
15. Valkovic P, Benetin J, Blazicek P, Valkovicova L, Gmitterova K, Kukumberg P. Reduced plasma homocysteine levels in levodopa/entacapone treated parkinson patients. Parkinsonism Relat Disord. 2005. 11:253–256.
Article
16. Zoccolella S, Lamberti P, Armenise E, de Mari M, Lamberti SV, Mastronardi R, et al. Plasma homocysteine levels in parkinson's disease: role of antiparkinsonian medications. Parkinsonism Relat Disord. 2005. 11:131–133.
Article
Full Text Links
  • DND
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr